Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) EBITDA (2018 - 2025)

Historic EBITDA for Arcturus Therapeutics Holdings (ARCT) over the last 8 years, with Q3 2025 value amounting to -$13.4 million.

  • Arcturus Therapeutics Holdings' EBITDA fell 9481.38% to -$13.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$66.7 million, marking a year-over-year decrease of 649.07%. This contributed to the annual value of -$80.9 million for FY2024, which is 17229.94% down from last year.
  • Arcturus Therapeutics Holdings' EBITDA amounted to -$13.4 million in Q3 2025, which was down 9481.38% from -$9.2 million recorded in Q2 2025.
  • Arcturus Therapeutics Holdings' EBITDA's 5-year high stood at $117.3 million during Q4 2022, with a 5-year trough of -$56.3 million in Q1 2021.
  • For the 5-year period, Arcturus Therapeutics Holdings' EBITDA averaged around -$18.0 million, with its median value being -$21.6 million (2022).
  • Its EBITDA has fluctuated over the past 5 years, first crashed by 47631.18% in 2021, then soared by 40351.24% in 2022.
  • Quarter analysis of 5 years shows Arcturus Therapeutics Holdings' EBITDA stood at -$38.7 million in 2021, then skyrocketed by 403.51% to $117.3 million in 2022, then tumbled by 109.98% to -$11.7 million in 2023, then crashed by 156.3% to -$30.0 million in 2024, then skyrocketed by 55.18% to -$13.4 million in 2025.
  • Its EBITDA was -$13.4 million in Q3 2025, compared to -$9.2 million in Q2 2025 and -$14.1 million in Q1 2025.